“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting - Episode 3

Third and Subsequent Line Options for Multiple Myeloma

January 29, 2021
Ajai Chari, MD, Mount Sinai Hospital

,
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center

,
Saad Z. Usmani, MD, FACP, Levine Cancer Institute

,
Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Experts in multiple myeloma discuss third-line and subsequent options for treating multiple myeloma, and BCMA-targeted approaches presented at the ASH 2020 Virtual Meeting.

Data from the following presentations are discussed:

  • CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. (Madduri, ASH 2020 Abstract 177)

  • Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. (Alsina, ASH 2020 Abstract130)

  • Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. (Mailankody, ASH 2020 Abstract129)

x